drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01142 | DB01173 | 1,264 | 358 | [
"DDInter593",
"DDInter1349"
] | Doxepin | Orphenadrine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
1264,
35,
358
]
],
[
[
1264,
63,
211
],
[
211,
1,
358
]
],
[
[
1264,
63,
272
],
[
272,
24,
358
]
],
[
[
1264,
1,
293
],
[
293,
4... | [
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Doxepin (Compound) resembles Orphenadrine (Compound) and
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Chlorphenirami... |
DB00853 | DB00978 | 1,686 | 739 | [
"DDInter1762",
"DDInter1084"
] | Temozolomide | Lomefloxacin | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Minor | 0 | [
[
[
1686,
23,
739
]
],
[
[
1686,
23,
945
],
[
945,
40,
739
]
],
[
[
1686,
62,
1176
],
[
1176,
1,
739
]
],
[
[
1686,
62,
1467
],
[
1467,
... | [
[
[
"Temozolomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Temozolomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
... | Temozolomide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Temozolomide may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin... |
DB00041 | DB01170 | 1,648 | 1,150 | [
"DDInter38",
"DDInter846"
] | Aldesleukin | Guanethidine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
1648,
24,
1150
]
],
[
[
1648,
24,
475
],
[
475,
24,
1150
]
],
[
[
1648,
24,
617
],
[
617,
63,
1150
]
],
[
[
1648,
25,
593
],
[
593,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budeso... |
DB08880 | DB13915 | 1,510 | 689 | [
"DDInter1771",
"DDInter146"
] | Teriflunomide | Axicabtagene ciloleucel | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express ant... | Major | 2 | [
[
[
1510,
25,
689
]
],
[
[
1510,
64,
599
],
[
599,
24,
689
]
],
[
[
1510,
25,
270
],
[
270,
24,
689
]
],
[
[
1510,
63,
1430
],
[
1430,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemt... | Teriflunomide may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Teriflunomide may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab ma... |
DB00261 | DB09118 | 702 | 1,580 | [
"DDInter93",
"DDInter1711"
] | Anagrelide | Stiripentol | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
702,
24,
1580
]
],
[
[
702,
25,
1409
],
[
1409,
24,
1580
]
],
[
[
702,
63,
168
],
[
168,
24,
1580
]
],
[
[
702,
24,
723
],
[
723,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
... | Anagrelide may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a m... |
DB09293 | DB13074 | 116 | 877 | [
"DDInter954",
"DDInter1110"
] | Iodide I-131 | Macimorelin | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
116,
24,
877
]
],
[
[
116,
63,
112
],
[
112,
23,
877
]
],
[
[
116,
63,
99
],
[
99,
24,
877
]
],
[
[
116,
24,
1004
],
[
1004,
24,... | [
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Propylthiour... |
DB00581 | DB00647 | 355 | 675 | [
"DDInter1018",
"DDInter528"
] | Lactulose | Dextropropoxyphene | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Moderate | 1 | [
[
[
355,
24,
675
]
],
[
[
355,
63,
494
],
[
494,
1,
675
]
],
[
[
355,
24,
1301
],
[
1301,
40,
675
]
],
[
[
355,
24,
820
],
[
820,
64... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Dextropropoxyphene (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol and Levacetylmethadol (Compound) resemble... |
DB00005 | DB00848 | 1,057 | 281 | [
"DDInter687",
"DDInter1044"
] | Etanercept | Levamisole | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Major | 2 | [
[
[
1057,
25,
281
]
],
[
[
1057,
24,
599
],
[
599,
24,
281
]
],
[
[
1057,
25,
1683
],
[
1683,
63,
281
]
],
[
[
1057,
24,
1136
],
[
1136,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levamisole"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzum... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Levamisole
Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may ca... |
DB06697 | DB11901 | 436 | 913 | [
"DDInter121",
"DDInter107"
] | Artemether | Apalutamide | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
436,
25,
913
]
],
[
[
436,
63,
303
],
[
303,
24,
913
]
],
[
[
436,
64,
609
],
[
609,
24,
913
]
],
[
[
436,
24,
1320
],
[
1320,
6... | [
[
[
"Artemether",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Artemether",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[... | Artemether may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Artemether may lead to a major life threatening interaction when taken with C... |
DB08896 | DB09098 | 292 | 98 | [
"DDInter1576",
"DDInter1700"
] | Regorafenib | Somatrem | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
292,
24,
98
]
],
[
[
292,
23,
1459
],
[
1459,
23,
98
]
],
[
[
292,
24,
159
],
[
159,
63,
98
]
],
[
[
292,
63,
609
],
[
609,
24,
... | [
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Regorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
],
[
... | Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Lar... |
DB00959 | DB01232 | 1,486 | 1,327 | [
"DDInter1191",
"DDInter1640"
] | Methylprednisolone | Saquinavir | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Major | 2 | [
[
[
1486,
25,
1327
]
],
[
[
1486,
64,
798
],
[
798,
40,
1327
]
],
[
[
1486,
25,
915
],
[
915,
40,
1327
]
],
[
[
1486,
6,
8374
],
[
8374,
... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavi... | Methylprednisolone may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Methylprednisolone may lead to a major life threatening interaction when taken with Atazanavir and Atazanavir (Compound) resembles Saquinavir (Compound)
Methylpredniso... |
DB01222 | DB11003 | 617 | 748 | [
"DDInter246",
"DDInter100"
] | Budesonide | Anthrax vaccine | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
617,
24,
748
]
],
[
[
617,
25,
676
],
[
676,
63,
748
]
],
[
[
617,
24,
1683
],
[
1683,
24,
748
]
],
[
[
617,
24,
1619
],
[
1619,
... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upa... | Budesonide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab... |
DB00349 | DB06168 | 902 | 1,531 | [
"DDInter401",
"DDInter281"
] | Clobazam | Canakinumab | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
902,
24,
1531
]
],
[
[
902,
40,
523
],
[
523,
24,
1531
]
],
[
[
902,
62,
1031
],
[
1031,
24,
1531
]
],
[
[
902,
24,
1093
],
[
1093,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Clobazam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a moderate i... | Clobazam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Clobazam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could ... |
DB01254 | DB09098 | 1,213 | 98 | [
"DDInter484",
"DDInter1700"
] | Dasatinib | Somatrem | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1213,
24,
98
]
],
[
[
1213,
24,
1612
],
[
1612,
62,
98
]
],
[
[
1213,
63,
608
],
[
608,
23,
98
]
],
[
[
1213,
23,
1459
],
[
1459,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine m... |
DB01259 | DB12141 | 392 | 971 | [
"DDInter1024",
"DDInter817"
] | Lapatinib | Gilteritinib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
392,
24,
971
]
],
[
[
392,
23,
1135
],
[
1135,
23,
971
]
],
[
[
392,
62,
1247
],
[
1247,
23,
971
]
],
[
[
392,
24,
466
],
[
466,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamet... |
DB00357 | DB06636 | 1,051 | 1,623 | [
"DDInter71",
"DDInter980"
] | Aminoglutethimide | Isavuconazonium | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
1051,
24,
1623
]
],
[
[
1051,
24,
466
],
[
466,
62,
1623
]
],
[
[
1051,
24,
1419
],
[
1419,
24,
1623
]
],
[
[
1051,
24,
1593
],
[
1593... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daroluta... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00193 | DB00604 | 534 | 1,425 | [
"DDInter1841",
"DDInter385"
] | Tramadol | Cisapride | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
534,
25,
1425
]
],
[
[
534,
25,
1311
],
[
1311,
1,
1425
]
],
[
[
534,
24,
717
],
[
717,
1,
1425
]
],
[
[
534,
6,
12523
],
[
12523,
... | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u... | Tramadol may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide (Compound) resembles Cisapride (Compound)
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide (Compound) resembles Cisapride (Compound)... |
DB01276 | DB06343 | 123 | 1,379 | [
"DDInter706",
"DDInter1766"
] | Exenatide | Teprotumumab | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Moderate | 1 | [
[
[
123,
24,
1379
]
],
[
[
123,
24,
1296
],
[
1296,
63,
1379
]
],
[
[
123,
63,
959
],
[
959,
24,
1379
]
],
[
[
123,
24,
1254
],
[
1254,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide... |
DB00348 | DB05812 | 254 | 1,374 | [
"DDInter1300",
"DDInter8"
] | Nitisinone | Abiraterone | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
254,
24,
1374
]
],
[
[
254,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
254,
24,
74
],
[
74,
62,
1374
]
],
[
[
254,
63,
798
],
[
798,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is cau... | Nitisinone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir and Boceprevir may cause a minor interaction that can limit clinical effects when taken with Abirater... |
DB05015 | DB11793 | 1,077 | 738 | [
"DDInter174",
"DDInter1297"
] | Belinostat | Niraparib | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1077,
24,
738
]
],
[
[
1077,
24,
1033
],
[
1033,
63,
738
]
],
[
[
1077,
63,
663
],
[
663,
24,
738
]
],
[
[
1077,
24,
496
],
[
496,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotr... |
DB00902 | DB09043 | 104 | 135 | [
"DDInter1168",
"DDInter36"
] | Methdilazine | Albiglutide | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
104,
24,
135
]
],
[
[
104,
63,
1647
],
[
1647,
23,
135
]
],
[
[
104,
63,
362
],
[
362,
24,
135
]
],
[
[
104,
24,
341
],
[
341,
2... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoi... |
DB11718 | DB11901 | 927 | 913 | [
"DDInter640",
"DDInter107"
] | Encorafenib | Apalutamide | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
927,
25,
913
]
],
[
[
927,
62,
112
],
[
112,
23,
913
]
],
[
[
927,
63,
1322
],
[
1322,
24,
913
]
],
[
[
927,
64,
600
],
[
600,
2... | [
[
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Encorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Encorafenib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and A... |
DB00445 | DB01218 | 322 | 1,493 | [
"DDInter655",
"DDInter852"
] | Epirubicin | Halofantrine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
322,
25,
1493
]
],
[
[
322,
18,
5998
],
[
5998,
46,
1493
]
],
[
[
322,
18,
2183
],
[
2183,
57,
1493
]
],
[
[
322,
21,
28810
],
[
28810... | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Epirubicin",
"{u} (Compound) downregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Epirubicin (Compound) downregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Halofantrine (Compound)
Epirubicin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Halofantrine (Compound)
Epirubicin (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effec... |
DB01320 | DB09036 | 651 | 812 | [
"DDInter783",
"DDInter1668"
] | Fosphenytoin | Siltuximab | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
651,
24,
812
]
],
[
[
651,
25,
792
],
[
792,
24,
812
]
],
[
[
651,
63,
1031
],
[
1031,
24,
812
]
],
[
[
651,
62,
608
],
[
608,
2... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivar... | Fosphenytoin may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline ... |
DB00349 | DB00350 | 902 | 1,214 | [
"DDInter401",
"DDInter1226"
] | Clobazam | Minoxidil | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Moderate | 1 | [
[
[
902,
24,
1214
]
],
[
[
902,
24,
530
],
[
530,
63,
1214
]
],
[
[
902,
40,
686
],
[
686,
63,
1214
]
],
[
[
902,
64,
475
],
[
475,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"... | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Clobazam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerba... |
DB00669 | DB00889 | 399 | 1,133 | [
"DDInter1730",
"DDInter840"
] | Sumatriptan | Granisetron | Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted FDA approval on 28 December 1992. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Major | 2 | [
[
[
399,
25,
1133
]
],
[
[
399,
6,
17589
],
[
17589,
45,
1133
]
],
[
[
399,
21,
29282
],
[
29282,
60,
1133
]
],
[
[
399,
63,
475
],
[
475,... | [
[
[
"Sumatriptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
]
],
[
[
"Sumatriptan",
"{u} (Compound) binds {v} (Gene)",
"HTR3A"
],
[
"HTR3A",
"{u} (Gene) is bound by {v} (Compound)",
"Granis... | Sumatriptan (Compound) binds HTR3A (Gene) and HTR3A (Gene) is bound by Granisetron (Compound)
Sumatriptan (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Granisetron (Compound)
Sumatriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine and M... |
DB00679 | DB06699 | 684 | 774 | [
"DDInter1796",
"DDInter493"
] | Thioridazine | Degarelix | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Major | 2 | [
[
[
684,
25,
774
]
],
[
[
684,
64,
521
],
[
521,
1,
774
]
],
[
[
684,
21,
28722
],
[
28722,
60,
774
]
],
[
[
684,
23,
112
],
[
112,
... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} ... | Thioridazine may lead to a major life threatening interaction when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Thioridazine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Degarelix (Compound)
Thioridazine may cause a minor interaction that can limit clinica... |
DB00749 | DB06779 | 59 | 365 | [
"DDInter699",
"DDInter470"
] | Etodolac | Dalteparin | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
59,
25,
365
]
],
[
[
59,
63,
305
],
[
305,
24,
365
]
],
[
[
59,
24,
1039
],
[
1039,
24,
365
]
],
[
[
59,
24,
738
],
[
738,
63,
... | [
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
... | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Etodolac may cause a moderate interaction that could exacerbate diseases whe... |
DB00843 | DB08875 | 479 | 1,618 | [
"DDInter583",
"DDInter262"
] | Donepezil | Cabozantinib | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
479,
24,
1618
]
],
[
[
479,
24,
112
],
[
112,
23,
1618
]
],
[
[
479,
62,
723
],
[
723,
24,
1618
]
],
[
[
479,
23,
384
],
[
384,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Donepezil may cause a minor interaction that can limit clinical effects when taken with Aprepitant and Apre... |
DB01242 | DB09080 | 1,237 | 144 | [
"DDInter410",
"DDInter1331"
] | Clomipramine | Olodaterol | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1237,
24,
144
]
],
[
[
1237,
25,
1011
],
[
1011,
24,
144
]
],
[
[
1237,
64,
11
],
[
11,
24,
144
]
],
[
[
1237,
63,
543
],
[
543,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingol... | Clomipramine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Clomipramine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate ... |
DB09134 | DB09420 | 1,552 | 1,074 | [
"DDInter966",
"DDInter953"
] | Ioversol | Iodide I-123 | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
1552,
24,
1074
]
],
[
[
1552,
64,
50
],
[
50,
24,
1074
]
],
[
[
1552,
63,
33
],
[
33,
24,
1074
]
],
[
[
1552,
24,
278
],
[
278,
... | [
[
[
"Ioversol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasala... | Ioversol may lead to a major life threatening interaction when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Ioversol may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may ca... |
DB00674 | DB11978 | 1,516 | 124 | [
"DDInter802",
"DDInter822"
] | Galantamine | Glasdegib | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1516,
24,
124
]
],
[
[
1516,
24,
112
],
[
112,
23,
124
]
],
[
[
1516,
1,
475
],
[
475,
24,
124
]
],
[
[
1516,
63,
79
],
[
79,
24... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Galantamine (Compound) resembles Morphine (Compound) and Morphine may cause a moderate interaction that coul... |
DB00603 | DB09048 | 303 | 555 | [
"DDInter1137",
"DDInter1284"
] | Medroxyprogesterone acetate | Netupitant | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Moderate | 1 | [
[
[
303,
24,
555
]
],
[
[
303,
64,
1101
],
[
1101,
23,
555
]
],
[
[
303,
24,
283
],
[
283,
62,
555
]
],
[
[
303,
24,
473
],
[
473,
2... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarote... | Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Fedr... |
DB08880 | DB11967 | 1,510 | 710 | [
"DDInter1771",
"DDInter210"
] | Teriflunomide | Binimetinib | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Major | 2 | [
[
[
1510,
25,
710
]
],
[
[
1510,
64,
1593
],
[
1593,
24,
710
]
],
[
[
1510,
25,
68
],
[
68,
63,
710
]
],
[
[
1510,
25,
951
],
[
951,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
... | Teriflunomide may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Teriflunomide may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may cause ... |
DB00056 | DB00059 | 816 | 1,560 | [
"DDInter814",
"DDInter1404"
] | Gemtuzumab ozogamicin | Pegaspargase | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Moderate | 1 | [
[
[
816,
24,
1560
]
],
[
[
816,
23,
1299
],
[
1299,
63,
1560
]
],
[
[
816,
24,
1367
],
[
1367,
63,
1560
]
],
[
[
816,
63,
1257
],
[
1257,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trova... | Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when take... |
DB00361 | DB08895 | 134 | 976 | [
"DDInter1939",
"DDInter1825"
] | Vinorelbine | Tofacitinib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
134,
25,
976
]
],
[
[
134,
23,
307
],
[
307,
23,
976
]
],
[
[
134,
63,
1461
],
[
1461,
23,
976
]
],
[
[
134,
24,
214
],
[
214,
6... | [
[
[
"Vinorelbine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil"... | Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E ... |
DB00286 | DB01217 | 380 | 630 | [
"DDInter439",
"DDInter95"
] | Conjugated estrogens | Anastrozole | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantag... | Moderate | 1 | [
[
[
380,
24,
630
]
],
[
[
380,
10,
11579
],
[
11579,
44,
630
]
],
[
[
380,
6,
8374
],
[
8374,
45,
630
]
],
[
[
380,
21,
28921
],
[
28921,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anastrozole"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) palliates {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
... | Conjugated estrogens (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Anastrozole (Compound)
Conjugated estrogens (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Anastrozole (Compound)
Conjugated estrogens (Compound) causes Dizziness (Side Effect) and Dizziness (Side E... |
DB00476 | DB00975 | 109 | 1,317 | [
"DDInter608",
"DDInter573"
] | Duloxetine | Dipyridamole | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
109,
24,
1317
]
],
[
[
109,
21,
28748
],
[
28748,
60,
1317
]
],
[
[
109,
24,
714
],
[
714,
63,
1317
]
],
[
[
109,
63,
1167
],
[
1167,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Duloxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Vertigo"
],
[
"Vertigo",
"{u} (Side Effect) is caused... | Duloxetine (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Dipyridamole (Compound)
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole
... |
DB05812 | DB06016 | 1,374 | 1,508 | [
"DDInter8",
"DDInter300"
] | Abiraterone | Cariprazine | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
1374,
24,
1508
]
],
[
[
1374,
25,
1593
],
[
1593,
63,
1508
]
],
[
[
1374,
63,
600
],
[
600,
24,
1508
]
],
[
[
1374,
24,
1250
],
[
1250... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizoti... | Abiraterone may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may c... |
DB00011 | DB00065 | 1,451 | 581 | [
"DDInter944",
"DDInter923"
] | Interferon alfa-n1 | Infliximab | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory... | Moderate | 1 | [
[
[
1451,
24,
581
]
],
[
[
1451,
25,
1477
],
[
1477,
63,
581
]
],
[
[
1451,
24,
33
],
[
33,
63,
581
]
],
[
[
1451,
24,
912
],
[
912,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telbivudine"
],
[
... | Interferon alfa-n1 may lead to a major life threatening interaction when taken with Telbivudine and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Ami... |
DB00390 | DB09065 | 1,252 | 760 | [
"DDInter554",
"DDInter424"
] | Digoxin | Cobicistat | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
1252,
24,
760
]
],
[
[
1252,
24,
1041
],
[
1041,
24,
760
]
],
[
[
1252,
24,
1033
],
[
1033,
63,
760
]
],
[
[
1252,
25,
609
],
[
609,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
],
[
... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib... |
DB08865 | DB11799 | 1,593 | 627 | [
"DDInter448",
"DDInter205"
] | Crizotinib | Bictegravir | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
1593,
24,
627
]
],
[
[
1593,
25,
1362
],
[
1362,
24,
627
]
],
[
[
1593,
63,
578
],
[
578,
24,
627
]
],
[
[
1593,
64,
478
],
[
478,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
... | Crizotinib may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a m... |
DB00745 | DB08882 | 307 | 1,281 | [
"DDInter1236",
"DDInter1070"
] | Modafinil | Linagliptin | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
307,
24,
1281
]
],
[
[
307,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
307,
21,
29081
],
[
29081,
60,
1281
]
],
[
[
307,
62,
251
],
[
251,
... | [
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Modafinil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Modafinil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Modafinil (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Linagliptin (Compound)
Modafinil may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Be... |
DB00106 | DB00193 | 618 | 534 | [
"DDInter4",
"DDInter1841"
] | Abarelix | Tramadol | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Moderate | 1 | [
[
[
618,
24,
534
]
],
[
[
618,
24,
1100
],
[
1100,
40,
534
]
],
[
[
618,
23,
112
],
[
112,
62,
534
]
],
[
[
618,
24,
1148
],
[
1148,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Tramadol (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limi... |
DB00377 | DB00526 | 1,494 | 1,555 | [
"DDInter1382",
"DDInter1355"
] | Palonosetron | Oxaliplatin | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
1494,
24,
1555
]
],
[
[
1494,
6,
7950
],
[
7950,
45,
1555
]
],
[
[
1494,
23,
1247
],
[
1247,
62,
1555
]
],
[
[
1494,
24,
79
],
[
79,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compou... | Palonosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Oxaliplatin
Palo... |
DB00065 | DB06595 | 581 | 1,491 | [
"DDInter923",
"DDInter1214"
] | Infliximab | Midostaurin | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
581,
25,
1491
]
],
[
[
581,
24,
112
],
[
112,
23,
1491
]
],
[
[
581,
24,
289
],
[
289,
24,
1491
]
],
[
[
581,
25,
270
],
[
270,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metron... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and... |
DB00553 | DB12455 | 92 | 933 | [
"DDInter1177",
"DDInter1336"
] | Methoxsalen | Omadacycline | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in ani... | Moderate | 1 | [
[
[
92,
24,
933
]
],
[
[
92,
24,
1517
],
[
1517,
25,
933
]
],
[
[
92,
25,
213
],
[
213,
25,
933
]
],
[
[
92,
63,
640
],
[
640,
25,
... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
],
... | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Omadacycline
Methoxsalen may lead to a major life threatening interaction when taken with Aminolevulinic acid and Aminolevulinic acid... |
DB01224 | DB01259 | 623 | 392 | [
"DDInter1553",
"DDInter1024"
] | Quetiapine | Lapatinib | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
623,
24,
392
]
],
[
[
623,
6,
4973
],
[
4973,
45,
392
]
],
[
[
623,
7,
10248
],
[
10248,
46,
392
]
],
[
[
623,
21,
29429
],
[
29429,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Quetiapine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Quetiapine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Quetiapine (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Lapatinib (Compound)
Quetiapine (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compoun... |
DB01067 | DB01165 | 959 | 1,539 | [
"DDInter826",
"DDInter1325"
] | Glipizide | Ofloxacin | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Major | 2 | [
[
[
959,
25,
1539
]
],
[
[
959,
64,
1467
],
[
1467,
1,
1539
]
],
[
[
959,
25,
945
],
[
945,
40,
1539
]
],
[
[
959,
64,
956
],
[
956,
... | [
[
[
"Glipizide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
]
],
[
[
"Glipizide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compoun... | Glipizide may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Glipizide may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Glipizide may lead to a major life... |
DB08908 | DB11581 | 713 | 1,456 | [
"DDInter564",
"DDInter1926"
] | Dimethyl fumarate | Venetoclax | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
713,
24,
1456
]
],
[
[
713,
63,
259
],
[
259,
24,
1456
]
],
[
[
713,
24,
1129
],
[
1129,
63,
1456
]
],
[
[
713,
24,
221
],
[
221,
... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Human a... |
DB00582 | DB01142 | 1,622 | 1,264 | [
"DDInter1946",
"DDInter593"
] | Voriconazole | Doxepin | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1622,
24,
1264
]
],
[
[
1622,
24,
401
],
[
401,
24,
1264
]
],
[
[
1622,
6,
6017
],
[
6017,
45,
1264
]
],
[
[
1622,
21,
29226
],
[
2922... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Voriconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Doxepin (Compound)
Voriconazole (Co... |
DB00029 | DB06441 | 25 | 936 | [
"DDInter99",
"DDInter283"
] | Anistreplase | Cangrelor | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Major | 2 | [
[
[
25,
25,
936
]
],
[
[
25,
23,
1631
],
[
1631,
62,
936
]
],
[
[
25,
24,
97
],
[
97,
24,
936
]
],
[
[
25,
24,
643
],
[
643,
63,
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Anistreplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Anistreplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Cangrelor
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin ma... |
DB00323 | DB00341 | 1,062 | 1,242 | [
"DDInter1829",
"DDInter343"
] | Tolcapone | Cetirizine | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _alle... | Moderate | 1 | [
[
[
1062,
24,
1242
]
],
[
[
1062,
24,
537
],
[
537,
63,
1242
]
],
[
[
1062,
21,
28692
],
[
28692,
60,
1242
]
],
[
[
1062,
63,
475
],
[
475... | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Tolcapone (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Cetirizine... |
DB00031 | DB00159 | 20 | 940 | [
"DDInter1764",
"DDInter903"
] | Tenecteplase | Icosapent | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Moderate | 1 | [
[
[
20,
24,
940
]
],
[
[
20,
25,
500
],
[
500,
63,
940
]
],
[
[
20,
24,
1347
],
[
1347,
63,
940
]
],
[
[
20,
64,
942
],
[
942,
24,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Icosapent"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxapa... | Tenecteplase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Icosapent
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may c... |
DB00491 | DB00703 | 127 | 997 | [
"DDInter1217",
"DDInter1167"
] | Miglitol | Methazolamide | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Moderate | 1 | [
[
[
127,
24,
997
]
],
[
[
127,
24,
471
],
[
471,
1,
997
]
],
[
[
127,
21,
28792
],
[
28792,
60,
997
]
],
[
[
127,
63,
176
],
[
176,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide (Compound) resembles Methazolamide (Compound)
Miglitol (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Methazolamide (Compound)
Migl... |
DB01309 | DB01406 | 1,254 | 984 | [
"DDInter933",
"DDInter472"
] | Insulin glulisine | Danazol | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Moderate | 1 | [
[
[
1254,
24,
984
]
],
[
[
1254,
63,
989
],
[
989,
1,
984
]
],
[
[
1254,
24,
1546
],
[
1546,
1,
984
]
],
[
[
1254,
63,
1026
],
[
1026,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Danazol (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) r... |
DB09034 | DB11978 | 1,313 | 124 | [
"DDInter1733",
"DDInter822"
] | Suvorexant | Glasdegib | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1313,
24,
124
]
],
[
[
1313,
23,
1135
],
[
1135,
23,
124
]
],
[
[
1313,
64,
475
],
[
475,
24,
124
]
],
[
[
1313,
63,
26
],
[
26,
... | [
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Suvorexant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Suvorexant may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Suvorexant may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate ... |
DB01229 | DB06414 | 973 | 655 | [
"DDInter1378",
"DDInter703"
] | Paclitaxel (protein-bound) | Etravirine | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
973,
24,
655
]
],
[
[
973,
6,
4973
],
[
4973,
45,
655
]
],
[
[
973,
21,
28723
],
[
28723,
60,
655
]
],
[
[
973,
63,
1101
],
[
1101,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Paclitaxel (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Paclitaxel (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Etravirine (Compound)
Pacl... |
DB00515 | DB01172 | 589 | 416 | [
"DDInter387",
"DDInter1004"
] | Cisplatin | Kanamycin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
589,
24,
416
]
],
[
[
589,
6,
7720
],
[
7720,
46,
416
]
],
[
[
589,
21,
31264
],
[
31264,
60,
416
]
],
[
[
589,
24,
712
],
[
712,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Cisplatin",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)"... | Cisplatin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Cisplatin (Compound) causes Nephrotoxicity (Side Effect) and Nephrotoxicity (Side Effect) is caused by Kanamycin (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine... |
DB00283 | DB00532 | 701 | 208 | [
"DDInter395",
"DDInter1152"
] | Clemastine | Mephenytoin | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
701,
24,
208
]
],
[
[
701,
35,
1242
],
[
1242,
24,
208
]
],
[
[
701,
24,
475
],
[
475,
24,
208
]
],
[
[
701,
24,
1219
],
[
1219,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken ... | Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Clemastine may cause a moderate interaction that coul... |
DB06723 | DB06777 | 115 | 780 | [
"DDInter58",
"DDInter348"
] | Aluminum hydroxide | Chenodeoxycholic acid | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decre... | Moderate | 1 | [
[
[
115,
24,
780
]
],
[
[
115,
62,
906
],
[
906,
1,
780
]
],
[
[
115,
21,
29707
],
[
29707,
60,
780
]
],
[
[
115,
63,
417
],
[
417,
... | [
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ur... | Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Ursodeoxycholic acid and Ursodeoxycholic acid (Compound) resembles Chenodeoxycholic acid (Compound)
Aluminum hydroxide (Compound) causes Lung disorder (Side Effect) and Lung disorder (Side Effect) is caused by Chenodeoxycho... |
DB00446 | DB08880 | 597 | 1,510 | [
"DDInter351",
"DDInter1771"
] | Chloramphenicol | Teriflunomide | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
597,
24,
1510
]
],
[
[
597,
24,
129
],
[
129,
63,
1510
]
],
[
[
597,
25,
1406
],
[
1406,
63,
1510
]
],
[
[
597,
24,
1191
],
[
1191,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Chloramphenicol may lead to a major life threatening interaction when taken with Neratinib and Nerat... |
DB06402 | DB09082 | 1,079 | 659 | [
"DDInter1756",
"DDInter1934"
] | Telavancin | Vilanterol | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1079,
24,
659
]
],
[
[
1079,
24,
927
],
[
927,
63,
659
]
],
[
[
1079,
64,
1069
],
[
1069,
24,
659
]
],
[
[
1079,
63,
485
],
[
485,
... | [
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Telavancin may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may caus... |
DB01136 | DB01268 | 772 | 1,151 | [
"DDInter305",
"DDInter1731"
] | Carvedilol | Sunitinib | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
772,
24,
1151
]
],
[
[
772,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
772,
7,
1986
],
[
1986,
46,
1151
]
],
[
[
772,
18,
2183
],
[
2183,
... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Carvedilol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Carvedilol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Carvedilol (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Sunitinib (Compound)
Carvedilol (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Sunitinib (Compound)
Carvedilol (Compo... |
DB01157 | DB04865 | 304 | 4 | [
"DDInter1875",
"DDInter1335"
] | Trimetrexate | Omacetaxine mepesuccinate | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
304,
24,
4
]
],
[
[
304,
24,
496
],
[
496,
63,
4
]
],
[
[
304,
63,
66
],
[
66,
24,
4
]
],
[
[
304,
24,
248
],
[
248,
24,
4... | [
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatiti... | Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Trimetrexate may cause a moderate interaction that could exacerbate diseases ... |
DB00741 | DB01267 | 167 | 519 | [
"DDInter885",
"DDInter1381"
] | Hydrocortisone | Paliperidone | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
167,
24,
519
]
],
[
[
167,
63,
1664
],
[
1664,
1,
519
]
],
[
[
167,
6,
7524
],
[
7524,
45,
519
]
],
[
[
167,
21,
29459
],
[
29459,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Hydrocortisone (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paliperidone (Compound)
Hydrocortisone (Compound) causes Skin discolouration... |
DB01015 | DB01177 | 1,247 | 77 | [
"DDInter1724",
"DDInter904"
] | Sulfamethoxazole | Idarubicin | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Minor | 0 | [
[
[
1247,
23,
77
]
],
[
[
1247,
6,
6017
],
[
6017,
45,
77
]
],
[
[
1247,
18,
10375
],
[
10375,
57,
77
]
],
[
[
1247,
21,
28987
],
[
28987,... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Sulfamethoxazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (C... | Sulfamethoxazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Sulfamethoxazole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Idarubicin (Compound)
Sulfamethoxazole (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Idarubicin... |
DB00564 | DB11718 | 1,236 | 927 | [
"DDInter293",
"DDInter640"
] | Carbamazepine | Encorafenib | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1236,
25,
927
]
],
[
[
1236,
24,
112
],
[
112,
23,
927
]
],
[
[
1236,
24,
372
],
[
372,
24,
927
]
],
[
[
1236,
63,
1324
],
[
1324,
... | [
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabin... |
DB00620 | DB06655 | 175 | 5 | [
"DDInter1855",
"DDInter1077"
] | Triamcinolone | Liraglutide | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
175,
24,
5
]
],
[
[
175,
40,
1103
],
[
1103,
23,
5
]
],
[
[
175,
24,
743
],
[
743,
23,
5
]
],
[
[
175,
63,
1252
],
[
1252,
23,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Triamcinolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can... |
DB01410 | DB09118 | 423 | 1,580 | [
"DDInter375",
"DDInter1711"
] | Ciclesonide | Stiripentol | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
423,
24,
1580
]
],
[
[
423,
40,
1573
],
[
1573,
24,
1580
]
],
[
[
423,
24,
384
],
[
384,
24,
1580
]
],
[
[
423,
63,
86
],
[
86,
... | [
[
[
"Ciclesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Ciclesonide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a mode... | Ciclesonide (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ciclesonide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that co... |
DB00196 | DB00289 | 600 | 847 | [
"DDInter743",
"DDInter132"
] | Fluconazole | Atomoxetine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Moderate | 1 | [
[
[
600,
24,
847
]
],
[
[
600,
24,
371
],
[
371,
40,
847
]
],
[
[
600,
23,
307
],
[
307,
1,
847
]
],
[
[
600,
25,
576
],
[
576,
1,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone (Compound) resembles Atomoxetine (Compound)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Atomoxetine (Compound... |
DB00845 | DB11057 | 1,490 | 720 | [
"DDInter406",
"DDInter1223"
] | Clofazimine | Mineral oil | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1490,
24,
720
]
],
[
[
1490,
24,
927
],
[
927,
63,
720
]
],
[
[
1490,
24,
1151
],
[
1151,
24,
720
]
],
[
[
1490,
25,
1069
],
[
1069,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Su... |
DB00060 | DB06589 | 912 | 1,250 | [
"DDInter947",
"DDInter1400"
] | Interferon beta-1a | Pazopanib | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
912,
24,
1250
]
],
[
[
912,
24,
1247
],
[
1247,
23,
1250
]
],
[
[
912,
24,
1151
],
[
1151,
24,
1250
]
],
[
[
912,
24,
214
],
[
214,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxa... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00539 | DB09054 | 11 | 384 | [
"DDInter1837",
"DDInter905"
] | Toremifene | Idelalisib | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
11,
25,
384
]
],
[
[
11,
25,
318
],
[
318,
23,
384
]
],
[
[
11,
64,
1230
],
[
1230,
23,
384
]
],
[
[
11,
24,
307
],
[
307,
23,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{... | Toremifene may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Toremifene may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a minor inter... |
DB00444 | DB04845 | 63 | 309 | [
"DDInter1765",
"DDInter1001"
] | Teniposide | Ixabepilone | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
63,
24,
309
]
],
[
[
63,
6,
8374
],
[
8374,
45,
309
]
],
[
[
63,
21,
28987
],
[
28987,
60,
309
]
],
[
[
63,
23,
307
],
[
307,
23... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Teniposide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Teniposide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Teniposide (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Ixabepilone (Compound)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil m... |
DB00445 | DB15091 | 322 | 676 | [
"DDInter655",
"DDInter1901"
] | Epirubicin | Upadacitinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
322,
25,
676
]
],
[
[
322,
63,
1461
],
[
1461,
23,
676
]
],
[
[
322,
24,
1430
],
[
1430,
24,
676
]
],
[
[
322,
25,
1593
],
[
1593,
... | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipule... |
DB00872 | DB01611 | 1,080 | 1,487 | [
"DDInter438",
"DDInter893"
] | Conivaptan | Hydroxychloroquine | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1080,
24,
1487
]
],
[
[
1080,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
1080,
63,
723
],
[
723,
24,
1487
]
],
[
[
1080,
24,
458
],
[
458... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Conivaptan",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) i... | Conivaptan (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with H... |
DB00477 | DB00835 | 216 | 100 | [
"DDInter363",
"DDInter245"
] | Chlorpromazine | Brompheniramine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
216,
24,
100
]
],
[
[
216,
24,
832
],
[
832,
24,
100
]
],
[
[
216,
1,
508
],
[
508,
24,
100
]
],
[
[
216,
63,
128
],
[
128,
24,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine... | Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Chlorpromazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate int... |
DB00738 | DB01166 | 485 | 477 | [
"DDInter1420",
"DDInter379"
] | Pentamidine | Cilostazol | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
485,
24,
477
]
],
[
[
485,
6,
8374
],
[
8374,
45,
477
]
],
[
[
485,
18,
16896
],
[
16896,
57,
477
]
],
[
[
485,
7,
9384
],
[
9384,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Pentamidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Pentamidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Pentamidine (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is downregulated by Cilostazol (Compound)
Pentamidine (Compound) upregulates TRIB3 (Gene) and TRIB3 (Gene) is downregulated by Cilostazol (Compound)
Pentamidi... |
DB01234 | DB11828 | 1,220 | 1,406 | [
"DDInter513",
"DDInter1281"
] | Dexamethasone | Neratinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
1220,
25,
1406
]
],
[
[
1220,
24,
1135
],
[
1135,
23,
1406
]
],
[
[
1220,
24,
392
],
[
392,
24,
1406
]
],
[
[
1220,
63,
1252
],
[
1252... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxe... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapati... |
DB00400 | DB06228 | 353 | 792 | [
"DDInter843",
"DDInter1609"
] | Griseofulvin | Rivaroxaban | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
353,
24,
792
]
],
[
[
353,
6,
8374
],
[
8374,
45,
792
]
],
[
[
353,
21,
28769
],
[
28769,
60,
792
]
],
[
[
353,
24,
307
],
[
307,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rivaroxaban (Compound)
Griseofulvin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Rivaroxaban (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00497 | DB00704 | 828 | 267 | [
"DDInter1366",
"DDInter1263"
] | Oxycodone | Naltrexone | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Major | 2 | [
[
[
828,
25,
267
]
],
[
[
828,
1,
1235
],
[
1235,
40,
267
]
],
[
[
828,
24,
173
],
[
173,
1,
267
]
],
[
[
828,
64,
475
],
[
475,
25,... | [
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} (Compound) resembles {v} (Compound... | Oxycodone (Compound) resembles Hydrocodone (Compound) and Hydrocodone (Compound) resembles Naltrexone (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Naloxone and Naloxone (Compound) resembles Naltrexone (Compound)
Oxycodone may lead to a major life threatening inter... |
DB00208 | DB00328 | 1,018 | 831 | [
"DDInter1804",
"DDInter921"
] | Ticlopidine | Indomethacin | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Moderate | 1 | [
[
[
1018,
24,
831
]
],
[
[
1018,
24,
1263
],
[
1263,
1,
831
]
],
[
[
1018,
6,
6017
],
[
6017,
45,
831
]
],
[
[
1018,
21,
28804
],
[
28804,... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
],
[... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac (Compound) resembles Indomethacin (Compound)
Ticlopidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Indomethacin (Compound)
Ticlopidine (Compound) causes Purpura (Side Effect) and Purpur... |
DB00975 | DB01105 | 1,317 | 222 | [
"DDInter573",
"DDInter1665"
] | Dipyridamole | Sibutramine | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1317,
24,
222
]
],
[
[
1317,
7,
2384
],
[
2384,
46,
222
]
],
[
[
1317,
21,
29152
],
[
29152,
60,
222
]
],
[
[
1317,
25,
802
],
[
802,
... | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Dipyridamole",
"{u} (Compound) upregulates {v} (Gene)",
"CDK6"
],
[
"CDK6",
"{u} (Gene) is upregulated by {v}... | Dipyridamole (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Sibutramine (Compound)
Dipyridamole (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Sibutramine (Compound)
Dipyridamole may lead to a major life threatening interaction when taken with Tinzaparin and Tinzapari... |
DB00697 | DB00835 | 876 | 100 | [
"DDInter1821",
"DDInter245"
] | Tizanidine | Brompheniramine | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
876,
24,
100
]
],
[
[
876,
24,
832
],
[
832,
24,
100
]
],
[
[
876,
63,
128
],
[
128,
24,
100
]
],
[
[
876,
24,
649
],
[
649,
63,... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],... | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Dexbromp... |
DB01075 | DB14509 | 1,376 | 1,399 | [
"DDInter569",
"DDInter1081"
] | Diphenhydramine | Lithium carbonate | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1376,
24,
1399
]
],
[
[
1376,
24,
1374
],
[
1374,
24,
1399
]
],
[
[
1376,
63,
506
],
[
506,
24,
1399
]
],
[
[
1376,
35,
820
],
[
820,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abirateron... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with De... |
DB09322 | DB11834 | 1,114 | 1,303 | [
"DDInter1966",
"DDInter849"
] | Zinc sulfate | Guselkumab | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Minor | 0 | [
[
[
1114,
23,
1303
]
],
[
[
1114,
62,
58
],
[
58,
24,
1303
]
],
[
[
1114,
23,
270
],
[
270,
63,
1303
]
],
[
[
1114,
62,
375
],
[
375,
... | [
[
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Guselkumab"
]
],
[
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alefacept"
],
[
... | Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocreliz... |
DB00717 | DB11767 | 1,197 | 1,583 | [
"DDInter1312",
"DDInter1643"
] | Norethisterone | Sarilumab | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
1197,
24,
1583
]
],
[
[
1197,
40,
890
],
[
890,
24,
1583
]
],
[
[
1197,
1,
1336
],
[
1336,
24,
1583
]
],
[
[
1197,
24,
1362
],
[
1362,... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a mo... | Norethisterone (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Norethisterone (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Sa... |
DB00514 | DB00964 | 506 | 1,617 | [
"DDInter527",
"DDInter110"
] | Dextromethorphan | Apraclonidine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Moderate | 1 | [
[
[
506,
24,
1617
]
],
[
[
506,
24,
1020
],
[
1020,
1,
1617
]
],
[
[
506,
24,
1084
],
[
1084,
40,
1617
]
],
[
[
506,
21,
28975
],
[
28975,... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Apraclonidine (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine and Lofexidine (Compound) resembles Apracloni... |
DB01097 | DB04896 | 1,377 | 901 | [
"DDInter1033",
"DDInter1220"
] | Leflunomide | Milnacipran | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Major | 2 | [
[
[
1377,
25,
901
]
],
[
[
1377,
21,
29271
],
[
29271,
60,
901
]
],
[
[
1377,
25,
405
],
[
405,
63,
901
]
],
[
[
1377,
64,
482
],
[
482,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Leflunomide",
"{u} (Compound) causes {v} (Side Effect)",
"Migraine"
],
[
"Migraine",
"{u} (Side Effect) is caused by {v} (Com... | Leflunomide (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Milnacipran (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Lef... |
DB00364 | DB00390 | 417 | 1,252 | [
"DDInter1717",
"DDInter554"
] | Sucralfate | Digoxin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Moderate | 1 | [
[
[
417,
24,
1252
]
],
[
[
417,
24,
1482
],
[
1482,
40,
1252
]
],
[
[
417,
24,
123
],
[
123,
62,
1252
]
],
[
[
417,
24,
1620
],
[
1620,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin (Compound) resembles Digoxin (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a minor interaction that can limit clini... |
DB00939 | DB01050 | 1,338 | 848 | [
"DDInter1135",
"DDInter900"
] | Meclofenamic acid | Ibuprofen | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1338,
24,
848
]
],
[
[
1338,
6,
7720
],
[
7720,
45,
848
]
],
[
[
1338,
21,
28652
],
[
28652,
60,
848
]
],
[
[
1338,
23,
16
],
[
16,
... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Meclofenamic acid",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (... | Meclofenamic acid (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Ibuprofen (Compound)
Meclofenamic acid (Compound) causes Colitis (Side Effect) and Colitis (Side Effect) is caused by Ibuprofen (Compound)
Meclofenamic acid may cause a minor interaction that can limit clinical effects when taken with Linaclot... |
DB00054 | DB12364 | 1,432 | 1,421 | [
"DDInter6",
"DDInter200"
] | Abciximab | Betrixaban | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1432,
25,
1421
]
],
[
[
1432,
23,
297
],
[
297,
23,
1421
]
],
[
[
1432,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
1432,
24,
992
],
[
992,
... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} ... | Abciximab may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Abciximab may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor... |
DB00845 | DB01259 | 1,490 | 392 | [
"DDInter406",
"DDInter1024"
] | Clofazimine | Lapatinib | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1490,
24,
392
]
],
[
[
1490,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1490,
21,
28803
],
[
28803,
60,
392
]
],
[
[
1490,
23,
112
],
[
112,
... | [
[
[
"Clofazimine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Clofazimine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Clofazimine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Clofazimine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Lapatinib (Compound)
Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronid... |
DB00467 | DB09272 | 1,467 | 412 | [
"DDInter644",
"DDInter632"
] | Enoxacin | Eluxadoline | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1467,
24,
412
]
],
[
[
1467,
25,
593
],
[
593,
24,
412
]
],
[
[
1467,
24,
663
],
[
663,
24,
412
]
],
[
[
1467,
23,
613
],
[
613,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Enoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
... | Enoxacin may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a... |
DB00532 | DB05679 | 208 | 1,683 | [
"DDInter1152",
"DDInter1907"
] | Mephenytoin | Ustekinumab | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
208,
24,
1683
]
],
[
[
208,
24,
1093
],
[
1093,
63,
1683
]
],
[
[
208,
24,
281
],
[
281,
24,
1683
]
],
[
[
208,
63,
305
],
[
305,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Levamisole and Lev... |
DB00308 | DB01249 | 347 | 258 | [
"DDInter901",
"DDInter958"
] | Ibutilide | Iodixanol | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Moderate | 1 | [
[
[
347,
24,
258
]
],
[
[
347,
24,
497
],
[
497,
1,
258
]
],
[
[
347,
21,
28844
],
[
28844,
60,
258
]
],
[
[
347,
40,
17
],
[
17,
24... | [
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
]
],
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
],
[
"I... | Ibutilide may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Ibutilide (Compound) causes Ventricular arrhythmia (Side Effect) and Ventricular arrhythmia (Side Effect) is caused by Iodixanol (Compound)
Ibutilide (Compound) resembl... |
DB01238 | DB06595 | 673 | 1,491 | [
"DDInter118",
"DDInter1214"
] | Aripiprazole | Midostaurin | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
673,
24,
1491
]
],
[
[
673,
62,
112
],
[
112,
23,
1491
]
],
[
[
673,
24,
761
],
[
761,
24,
1491
]
],
[
[
673,
63,
888
],
[
888,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Aripiprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin an... |
DB00575 | DB01105 | 1,020 | 222 | [
"DDInter412",
"DDInter1665"
] | Clonidine | Sibutramine | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1020,
24,
222
]
],
[
[
1020,
6,
8374
],
[
8374,
45,
222
]
],
[
[
1020,
21,
29152
],
[
29152,
60,
222
]
],
[
[
1020,
1,
1617
],
[
1617,... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Clonidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Clonidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Clonidine (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Sibutramine (Compound)
Clonidine (Compound) resembles Apraclonidine (Compound) and Apra
Clonidine may cause a moderate interaction that cou... |
DB01126 | DB12500 | 1,260 | 283 | [
"DDInter611",
"DDInter714"
] | Dutasteride | Fedratinib | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestos... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1260,
24,
283
]
],
[
[
1260,
24,
351
],
[
351,
23,
283
]
],
[
[
1260,
63,
1419
],
[
1419,
24,
283
]
],
[
[
1260,
24,
951
],
[
951,
... | [
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Dutasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Dutasteride may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.